The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Aim The aim of this study was to assess the effects of metformin and rosiglitazone on insulin resistance and serum androgen levels in both obese and lean patients with polycystic ovary syndrome (PCOS).Materials and methods Forty lean [body mass index (BMI) < 25 kg/m2] and 40 overweight and obese (BMI > 25 kg/m2) patients were included in the study. Waist and hip measurements, serum sex steroid levels, insulin response to 75-g oral glucose tolerance test, fasting insulin, fasting C-peptide levels and homeostasis model assessment of insulin resistance (HOMA-IR) were determined in all patients. The degree of hirsutism was determined by the Ferriman-Gallwey scoring system. Patients were divided into two groups, with 40 (20 overweight and obese; 20 non-obese) patients each. One group was treated with metformin (MET group) 850 mg bid while the other received rosiglitazone (ROSI group) 4 mg/day for 12 weeks. All measurements were repeated at the end of this period.Results After the 12-week treatment period, HOMA-IR, area under the curve of insulin, fasting insulin and C-peptide levels were observed to have be decreased significantly in all groups. The decrease in the parameters mentioned above was similar in the four groups. The serum levels of free testosterone, androstenedione and DHEA-S decreased in all groups, but the decrease was statistically significant only in the ROSI groups. Within the lean MET group one patient became pregnant and was hence excluded from the final data analysis. Menstruations became regular after metformin therapy in 41.6% of lean and 35.7% of obese patients who had menstrual disturbance prior to the study. Rosiglitazone therapy improved menstrual disturbance in 61.5 % of lean and 53.8% of obese patients.Conclusions Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well. Rosiglitazone seemed to be more effective in decreasing the androgen levels and in achieving slightly greater improvement in menstrual disturbance than metformin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies have shown that alleviating insulin resistance is closely associated with improving menstrual cycles, ovulation, and in vitro fertilization results in PCOS [28-30].”
From Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial (2024) · cites this paper as [28]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 47 · Cited by 77
Metadata
- Authors
- Yilmaz, M., Biri, A., Karakoç, A., Törüner, F., Bingöl, B., Çakir, N., Tiras, B., Ayvaz, G., & Arslan, M.
- Affiliations
- Gazi University (TR)
- Venue
- Journal of Endocrinological Investigation
- Published
- 2005-02
- Volume
- 28
- Issue
- 2
- Pages
- 1003-1008
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W1996806039
- Cited by
- 77
- References
- 47
- Citations by year
- 2024: 3 · 2023: 1 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 4 · 2012: 2
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, rosiglitazone, metformin, insulin resistance, androgen levels, obesity, hirsutism, menstrual irregularity, free testosterone, androstenedione, dehydroepiandrosterone sulfate, insulin sensitivity, PPARγ agonists, thiazolidinediones
- MeSH terms
- Rosiglitazone, Adult, Androgens, Blood Glucose, Fasting, Female, Follicle Stimulating Hormone, Glucose Tolerance Test, Hirsutism, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Luteinizing Hormone, Menstrual Cycle, Menstruation, Metformin, Obesity, Polycystic Ovary Syndrome, Thinness, Body Mass Index, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. https://app.cochat.ai/papers/10.1007/bf03345339
- The paper
- Yilmaz, M., Biri, A., Karakoç, A., Törüner, F., Bingöl, B., Çakir, N., Tiras, B., Ayvaz, G., & Arslan, M. (2005). The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. Journal of Endocrinological Investigation. https://doi.org/10.1007/bf03345339
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.